{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:44:39Z","timestamp":1757702679794},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p>\n            Monoamine oxidase inhibitors are associated with dietary tyramine interactions that can induce hypertensive crises. Rasagiline mesylate is a novel irreversible selective monoamine oxidase type B inhibitor for Parkinson disease that may have a low risk of interaction with dietary tyramine because of its selectivity. To study interactions of rasagiline with diets unrestricted in tyramine-containing foods, we incorporated transtelephonic, self-monitoring of the blood pressure (BP) into a randomized, placebo-controlled trial of rasagiline 0.5 and 1.0 mg daily in 414 levodopa-treated Parkinson patients with motor fluctuations. The proportion of patients with a systolic BP increase of &gt;30 mm Hg was the primary BP end point. In 13 968 self-measured readings at baseline, the proportion of systolic BP values that increased by &gt;30 mm Hg after a meal ranged from 9.5% to 12.9% in the 3 treatment groups. In 25 733 BPs obtained postrandomization, the proportion of values with a &gt;30-mm Hg systolic postprandial increase was 15% in the placebo group, 15% in the rasagiline 0.5-mg group, and 11% in the rasagiline 1-mg group after 3 weeks of double-blind therapy and 13%, 14%, and 12%, respectively, after 26 weeks of treatment (\n            <jats:italic>P<\/jats:italic>\n            value was not significant for all of the comparisons among treatment groups). A postprandial increase in systolic BP to &gt;180 mm Hg at any time after randomization was seen in 3.3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.108.115873","type":"journal-article","created":{"date-parts":[[2008,8,5]],"date-time":"2008-08-05T00:59:39Z","timestamp":1217897979000},"page":"587-593","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease"],"prefix":"10.1161","volume":"52","author":[{"given":"William B.","family":"White","sequence":"first","affiliation":[{"name":"From the Division of Hypertension and Clinical Pharmacology (W.B.W.), Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Conn; Medical Affairs (P.S.), Teva Neuroscience, Inc, Horsham, Pa; and the Department of Neurology (S.R.S.), University of Rochester, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis","family":"Salzman","sequence":"additional","affiliation":[{"name":"From the Division of Hypertension and Clinical Pharmacology (W.B.W.), Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Conn; Medical Affairs (P.S.), Teva Neuroscience, Inc, Horsham, Pa; and the Department of Neurology (S.R.S.), University of Rochester, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Schwid","sequence":"additional","affiliation":[{"name":"From the Division of Hypertension and Clinical Pharmacology (W.B.W.), Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Conn; Medical Affairs (P.S.), Teva Neuroscience, Inc, Horsham, Pa; and the Department of Neurology (S.R.S.), University of Rochester, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.12.1239"},{"key":"e_1_3_3_2_2","first-page":"113","volume":"126","year":"1989","unstructured":"Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand. 1989; 126 (suppl): 113\u2013115.","journal-title":"Acta Neurol Scand"},{"key":"e_1_3_3_3_2","first-page":"163","volume":"25","year":"1987","unstructured":"Ulm G, Fornandi F. R-(\u2212)-deprenyl in the treatment of end-of-dose akinesia. J Neurol Transm. 1987; 25 (suppl): 163\u2013172.","journal-title":"J Neurol Transm"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.561"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Marley E Blackwell B. Interactions of monoamine oxidase inhibitors and foodstuffs. In: Garratini S Golden A Hawking F Kopin I eds. Advances in Pharmacology and Chemotherapy. New York NY: Academic Press; 1970: 189\u2013239.","DOI":"10.1016\/S1054-3589(08)60597-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431747"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200108000-00004"},{"key":"e_1_3_3_10_2","first-page":"145","volume":"5","year":"2000","unstructured":"Denolle T, Waeber B, Kjeldsen S, Parati G, Wilson M, Asmar R. Self-measurement of blood pressure in clinical trials and therapeutic applications. Blood Press Monit. 2000; 5: 145\u2013149.","journal-title":"Blood Press Monit"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200210000-00007"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000150859.47929.8e"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21048"},{"key":"e_1_3_3_14_2","first-page":"540","volume":"95","year":"1988","unstructured":"Prasad A, Glover V, Goodwin BL, Sandler M, Signy M, Smith SE. Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment. Psychopharmacology. 1988; 95: 540\u2013543.","journal-title":"Psychopharmacology"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289852"},{"key":"e_1_3_3_16_2","first-page":"83","volume":"5","year":"1991","unstructured":"Haigh RA, Harper GD, Burton R, Macdonald JA, Potter JF. Possible impairment of the sympathetic nervous system response to post-prandial hypertension in elderly hypertensive patients. J Hum Hypertens. 1991; 5: 83\u201389.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2006.00839.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-813X(03)00103-7"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200605000-00006"},{"key":"e_1_3_3_20_2","first-page":"196","volume":"56","year":"1995","unstructured":"Sweet RA, Brown EJ, Heimberg RG, Clafre L, Scanga DM, Cornelius JR, Dube S, Forsyth KM, Holt CS. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatr. 1995; 56: 196\u2013201.","journal-title":"J Clin Psychiatr"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.108.115873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:22:31Z","timestamp":1715592151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.108.115873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.108.115873"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.108.115873","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"2008-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}